The role of ventricular assist device in children

Delmo, Eva Maria Javier; Javier, Mariano Francisco del Maria; Hetzer, Roland

doi:10.21037/cdt-20-282

Cited by 5 publications

(4 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite treatment success, our case raises multiple fundamental questions that have to be addressed not only to forward The viability of VADs for overcoming waiting times in patients with heart failure of different etiologies has been widely discussed and established. 5,6 However, discussions on the use of VADs to bridge severe heart failure in the setting of ongoing oncological disease are scarce. It is, therefore, crucial to acknowledge and incorporate various deleterious outcomes when considering their implantation in the aforementioned setting.…”

Section: Discussionmentioning

confidence: 99%

Toxicity-induced Cardiomyopathy in a Patient with Femoral Sarcoma: Heart Transplantation After Support with Ventricular Assist Device as Bridge to Transplantability

Javier

Delmo²,

Hetzer³

2022

ASAIO Journal

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Toxicity-induced Cardiomyopathy in a Patient with Femoral Sarcoma: Heart Transplantation After Support with Ventricular Assist Device as Bridge to Transplantability

Javier

Delmo²,

Hetzer³

2022

ASAIO Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…Such treatment options include ECMO and ventricular assist devices (VAD) as bridge therapies with cardiac transplantation as the ultimate treatment goal. ECMO-cardiopulmonary resuscitation (ECPR) in cases of myocarditis or myocardial dysfunction should be considered as early as possible, provided the necessary facilities are readily available at the center [ 44 , 45 ]. The underlying causes of cardiogenic shock should also be addressed after initial resuscitation and stabilization like cardiac arrhythmias and myocarditis.…”

Section: Management Of Shock In Children—recent Advancesmentioning

confidence: 99%

Advances in Shock Management and Fluid Resuscitation in Children

Gupta

Sankar

2023

Indian J Pediatr

View full text Add to dashboard Cite

Shock in children is associated with significant mortality and morbidity, particularly in resource-limited settings. The principles of management include early recognition, fluid resuscitation, appropriate inotropes, antibiotic therapy in sepsis, supportive therapy for organ dysfunction, and regular hemodynamic monitoring. During the past decade, each step has undergone several changes and evolved as evidence that has been translated into recommendations and practice. There is a paradigm shift from protocolized-based care to personalized management, from liberal strategies to restrictive strategies in terms of fluids, blood transfusion, ventilation, and antibiotics, and from clinical monitoring to multimodal monitoring using bedside technologies. However, uncertainties are still prevailing in terms of the volume of fluids, use of steroids, and use of extracorporeal and newer therapies while managing shock. These changes have been summarized along with evidence in this article with the aim of adopting an evidence-based approach while managing children with shock.

show abstract

“…Most infants with DCM die within the first year of their lives as soon as they are diagnosed, with survival rates at one and five years of 79% and 61%, respectively [ 38 - 45 ]. Most children die of heart failure in early childhood, and the rest of the children whose ventricular function did not fully recover can fail due to arrhythmias.…”

Section: Reviewmentioning

confidence: 99%

Dilated Cardiomyopathy in Children: Early Detection and Treatment

Mallavarapu¹,

Taksande²

2022

Cureus

View full text Add to dashboard Cite

Cardiomyopathy is segregated into primary and secondary categories, leading to different phenotypes, including dilated, hypertrophic, and restrictive patterns. Dilated cardiomyopathy (DCM) is a mixed bag of heart diseases with the unique features of cardiac dilatation and subnormal to poor myocardial contractility. Dilated cardiomyopathy in the pediatric age group is generally characterized by unobstructed, dilated, and contracting left ventricular chamber defects and is associated with heart failure. Other causes include genetic juvenile-onset cardiomyopathy, drug-induced cardiomyopathy, stress-induced cardiomyopathy, hemochromatosis, endocrine causes (thyroid disorder and pheochromocytoma), autoimmune diseases, and nutritional deficiencies (selenium and thiamine). It is characterized by thinning of the left ventricle, a dilated left ventricle or biventricular dilatation, left ventricular systolic dysfunction, left ventricular diastolic dysfunction, global hypokinesia, and cardiomegaly (seen on a chest X-ray). Decreased cardiac output leads to fatigue, cachexia, narrow pulse pressure, dicrotic pulse/hypokinetic pulse, dyspnea, cool extremities, decreased blood supply to the brain (cognitive dysfunction), and reduced blood supply to the kidney (renal failure). Left ventricular diastolic dysfunction can result in dyspnea, orthopnea, and paroxysmal nocturnal dyspnea. Cardiomyopathy can also occur with or without left ventricular dysfunction, as in left ventricular non-compaction cardiomyopathy (LVNC), which is a rare heart disease occurring due to two (likely) pathogenic nonsense mutations: DSG2-p.S363X and TBX20-p.D278X. The study of familial forms of LVNC is helpful for risk prediction and genetic counseling of relatives. Right ventricular chamber failure can be identified on the electrocardiogram as sinus tachycardia and non-specific ST/T changes. The complications include arrhythmia (atrial fibrillation) and thromboembolism (left ventricular mural thrombosis). It is of utmost importance in the field of heart transplantation as the definitive treatment of the disease. Heart transplantation is now an acceptable treatment option for patients with dilated cardiomyopathy. This short review highlights different methods for the detection and diagnosis of dilated cardiomyopathy and the treatment modalities available for the same.

show abstract

The role of ventricular assist device in children

Cited by 5 publications

References 61 publications

Toxicity-induced Cardiomyopathy in a Patient with Femoral Sarcoma: Heart Transplantation After Support with Ventricular Assist Device as Bridge to Transplantability

Toxicity-induced Cardiomyopathy in a Patient with Femoral Sarcoma: Heart Transplantation After Support with Ventricular Assist Device as Bridge to Transplantability

Advances in Shock Management and Fluid Resuscitation in Children

Dilated Cardiomyopathy in Children: Early Detection and Treatment

Contact Info

Product

Resources

About